Showing results (21-30 of 392) with videos related to
Sort By:
Pageof 40
Cancer Treatment Reviews|January 13, 2017
Front-line treatment of CLL in the era of novel agentsTadeusz Robak, Stephan Stilgenbauer, Alessandra TedeschiCurrent Drug Targets|November 1, 2006
Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemiaDirk Winkler, Hartmut Döhner, Stephan StilgenbauerSeminars in Oncology|April 18, 2006
Risk stratification in chronic lymphocytic leukemiaTill Seiler, Hartmut Döhner, Stephan StilgenbauerBritish Journal of Haematology|March 12, 2026
Short and complex-Telomeres and genomes in CLLBilly Michael Chelliah Jebaraj, Stephan StilgenbauerCancers|January 8, 2023
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?Karol D Urbanek, Stephan Stilgenbauer, Daniel MertensClinical Advances in Hematology & Oncology : H&O|January 4, 2011
Clinical roundtable monograph. New alternatives in CLL therapy: managing adverse eventsAsher Chanan-Khan, Thomas Kipps, Stephan StilgenbauerBlood Reviews|March 26, 2011
Importance of genetics in chronic lymphocytic leukemiaThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.Leukemia & Lymphoma|May 3, 2008
Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implicationsThorsten Zenz, Daniel Mertens, Hartmut Döhner, et al.Cell Cycle (Georgetown, Tex.)|December 23, 2008
Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathwayThorsten Zenz, Axel Benner, Hartmut Döhner, et al.Blood Cancer Journal|January 8, 2026
First-line treatment for CLL in the era of targeted therapyMatthew S Davids, Stephan Stilgenbauer, Constantine S TamPageof 40